Reinilde Heyrman is Chief Clinical Dev. Officer at Bellerophon Therapeutics, Inc. (BLPH). They have made 1 open-market trade across 1 company since 2015, most recently 2015-02-19.
CIK 0001630929
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $18K since 2015, never a sale. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| BLPH | 9,483 | $972 |
Shares reported on the most recent Form 4, priced at the 2015-02-23 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| BLPH | BUY | 2015-02-19 | 2015-02-23 | $12.00 | $18K | -13.1% | -0.7% | -0.7% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.